公开(公告)号：US09950065B2

公开(公告)日：2018-04-24

申请号：US15023052

申请日：2013-09-26

Applicant: BIONTECH AG ,  TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbH ,  UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ

Inventor： Ugur Sahin ,  Heinrich Haas ,  Sebastian Kreiter ,  Yves Hüsemann ,  Mustafa Diken ,  Kerstin Reuter ,  Hossam Hefresha

IPC: A61K39/39 ,  A61K39/00 ,  A61K9/127 ,  A61K9/50 ,  A61K31/675 ,  C12N15/88

CPC classification number: A61K39/39 ,  A61K9/1271 ,  A61K9/1277 ,  A61K9/5073 ,  A61K31/675 ,  A61K39/0011 ,  A61K2039/55505 ,  A61K2039/55511 ,  A61K2039/55516 ,  A61K2039/55555 ,  A61K2039/55561 ,  A61K2039/572 ,  C12N15/88 ,  C12N2810/10

Abstract: The present invention relates to RNA decorated particles such as RNA decorated lipid particles, preferably to RNA decorated liposomes. Further, the present invention relates to a pharmaceutical composition comprising RNA decorated particles such as RNA decorated lipid particles, preferably RNA decorated liposomes. Said pharmaceutical composition is useful for inducing an immune response. It is also useful in a prophylactic and/or therapeutic treatment of a disease involving an antigen. Furthermore, the present invention relates to a method for producing the RNA decorated particles such as RNA decorated lipid particles, preferably RNA decorated liposomes.

公开(公告)号：US10106800B2

公开(公告)日：2018-10-23

申请号：US15217555

申请日：2016-07-22

Applicant: BioNTech AG

Inventor： Ugur Sahin ,  Silke Holtkamp ,  Ozlem Tureci ,  Sebastian Kreiter

IPC: C12N15/00 ,  C12P21/06 ,  C12N15/68 ,  C12N15/67 ,  C12N15/85

Abstract: It was the object of the present invention to provide RNA with increased stability and translation efficiency and means for obtaining such RNA. It should be possible to obtain increased grades of expression by using said RNA in gene therapy approaches.

公开(公告)号：US20150086612A1

公开(公告)日：2015-03-26

申请号：US14388192

申请日：2013-03-25

Applicant: BioNTech AG ,  TRON - Translationale Onkologie an der Johannes Gutenberg-Universität Mainz Gemeinnützge GmbH ,  Universitätsmedizin der Johannes Gutenber-Universität Mains

Inventor： Ugur Sahin ,  Heinrich Haas ,  Sebastian Kreiter ,  Mustafa Diken ,  Daniel Fritz ,  Martin Meng ,  Lena Mareen Kranz ,  Kerstin Reuter

IPC: A61K48/00 ,  A61K39/00 ,  A61K9/127

Abstract: The present invention is in the field of immunotherapy, in particular tumor immunotherapy. The present invention provides pharmaceutical formulations for delivering RNA to antigen presenting cells such as dendrite cells (DCs) in the spleen after systemic administration. In particular, the formulations described herein enable to induce an immune response after systemic administration of antigen-coding RNA.

Abstract translation: 本发明涉及免疫治疗领域，特别是肿瘤免疫治疗领域。 本发明提供用于在全身给药后将脾脏中的抗原提呈细胞例如树突状细胞（DC）递送RNA的药物制剂。 特别地，本文描述的制剂能够在全身给予抗原编码RNA之后诱导免疫应答。

公开(公告)号：US20140134201A1

公开(公告)日：2014-05-15

申请号：US14152597

申请日：2014-01-10

Applicant: BioNTech AG

Inventor： Ozlem Tureci ,  Ugur Sahin ,  Sebastian Kreiter

IPC: A61K47/48

CPC classification number: A61K47/64 ,  A61K48/00 ,  C07K14/4748 ,  C07K14/70539 ,  C07K2319/02 ,  C07K2319/03

Abstract: The present invention relates to fusion molecules of antigens, the nucleic acids coding therefor and the use of such fusion molecules and nucleic acids. In particular, said invention relates to fusion molecules, comprising an antigen and the trans-membrane region and cytoplasmic region of a MHC molecule and/or the cytoplasmic region of a MHC or a SNARE molecule.

Abstract translation: 本发明涉及抗原的融合分子，其编码的核酸以及这种融合分子和核酸的使用。 特别地，本发明涉及融合分子，其包含MHC或SNARE分子的MHC分子和/或细胞质区域的抗原和跨膜区域和胞质区域。

公开(公告)号：US20190062762A1

公开(公告)日：2019-02-28

申请号：US16143520

申请日：2018-09-27

Applicant: BioNTech AG

Inventor： Ugur Sahin ,  Silke Holtkamp ,  Ozlem Tureci ,  Sebastian Kreiter

IPC: C12N15/68 ,  C12N15/85 ,  C12N15/67

Abstract: It was the object of the present invention to provide RNA with increased stability and translation efficiency and means for obtaining such RNA. It should be possible to obtain increased grades of expression by using said RNA in gene therapy approaches.

公开(公告)号：US20180177885A1

公开(公告)日：2018-06-28

申请号：US15895402

申请日：2018-02-13

Applicant: BioNTech AG

Inventor： Ozlem Tureci ,  Ugur Sahin ,  Sebastian Kreiter

IPC: A61K47/64 ,  C07K14/74 ,  C07K14/47 ,  A61K48/00

CPC classification number: A61K47/64 ,  A61K48/00 ,  C07K14/4748 ,  C07K14/70539 ,  C07K2319/02 ,  C07K2319/03

Abstract: The present invention relates to fusion molecules of antigens, the nucleic acids coding therefor and the use of such fusion molecules and nucleic acids. In particular, said invention relates to fusion molecules, comprising an antigen and the trans-membrane region and cytoplasmic region of a MHC molecule and/or the cytoplasmic region of a MHC or a SNARE molecule.

公开(公告)号：US20170009244A1

公开(公告)日：2017-01-12

申请号：US15217555

申请日：2016-07-22

Applicant: BioNTech AG

Inventor： Ugur Sahin ,  Silke Holtkamp ,  Ozlem Tureci ,  Sebastian Kreiter

IPC: C12N15/68 ,  C12N15/85

CPC classification number: C12N15/68 ,  C12N15/67 ,  C12N15/85

Abstract: It was the object of the present invention to provide RNA with increased stability and translation efficiency and means for obtaining such RNA. It should be possible to obtain increased grades of expression by using said RNA in gene therapy approaches.

Abstract translation: 本发明的目的是提供具有增加的稳定性和翻译效率的RNA以及获得这种RNA的手段。 通过在基因治疗方法中使用所述RNA可以获得更高等级的表达。

公开(公告)号：US20160250323A1

公开(公告)日：2016-09-01

申请号：US15023052

申请日：2013-09-26

Applicant: BIONTECH AG ,  TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄT SMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ ,  UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ

Inventor： Ugur Sahin ,  Heinrich Haas ,  Sebastian Kreiter ,  Yves Hüsemann ,  Mustafa Diken ,  Kerstin Reuter ,  Hossam Hefesha

IPC: A61K39/39 ,  A61K39/00

CPC classification number: A61K39/39 ,  A61K9/1271 ,  A61K9/1277 ,  A61K9/5073 ,  A61K31/675 ,  A61K39/0011 ,  A61K2039/55505 ,  A61K2039/55511 ,  A61K2039/55516 ,  A61K2039/55555 ,  A61K2039/55561 ,  A61K2039/572 ,  C12N15/88 ,  C12N2810/10

Abstract: The present invention relates to RNA decorated particles such as RNA decorated lipid particles, preferably to RNA decorated liposomes. Further, the present invention relates to a pharmaceutical composition comprising RNA decorated particles such as RNA decorated lipid particles, preferably RNA decorated liposomes. Said pharmaceutical composition is useful for inducing an immune response. It is also useful in a prophylactic and/or therapeutic treatment of a disease involving an antigen. Furthermore, the present invention relates to a method for producing the RNA decorated particles such as RNA decorated lipid particles, preferably RNA decorated liposomes.

Abstract translation: 本发明涉及RNA修饰的颗粒，例如RNA修饰的脂质颗粒，优选涉及RNA修饰的脂质体。 此外，本发明涉及包含RNA修饰的颗粒如RNA修饰的脂质颗粒，优选RNA修饰的脂质体的药物组合物。 所述药物组合物可用于诱导免疫应答。 它也可用于预防和/或治疗涉及抗原的疾病。 此外，本发明涉及用于制备RNA装饰颗粒的方法，例如RNA修饰的脂质颗粒，优选RNA修饰的脂质体。